We appreciate the interest and comments by Dr Eggenberger in regard to our recent article examining the incidence of optic neuritis in patients using anti–tumor necrosis factor therapies. His letter highlights many important aspects of our paper and the methodologies inherent to observational study designs. We agree with Dr Eggenberger's thoughts regarding the importance of case ascertainment. As we pointed out in our manuscript, we were not able to review the medical records of the identified cases, and we accordingly relied upon a validated algorithm that consisted of multiple diagnostic codes consistent with acute optic neuritis. When performing our validation (Read more...)

Full Story →